MARKET

GYRE

GYRE

Gyre Therapeutics Inc
NASDAQ
6.87
-0.18
-2.49%
After Hours: 6.84 -0.03 -0.36% 16:09 10/12 EDT
OPEN
7.00
PREV CLOSE
7.04
HIGH
7.07
LOW
6.85
VOLUME
81.95K
TURNOVER
--
52 WEEK HIGH
9.42
52 WEEK LOW
5.44
MARKET CAP
765.52M
P/E (TTM)
-35.1871
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Rezolute (RZLT), Actinium Pharmaceuticals (ATNM) and Gyre Therapeutics (GYRE)
TipRanks · 10/05 15:40
Weekly Report: what happened at GYRE last week (0928-1002)?
Weekly Report · 10/05 09:09
Weekly Report: what happened at GYRE last week (0921-0925)?
Weekly Report · 09/28 09:09
Weekly Report: what happened at GYRE last week (0914-0918)?
Weekly Report · 09/21 09:09
Weekly Report: what happened at GYRE last week (0907-0911)?
Weekly Report · 09/14 09:09
Weekly Report: what happened at GYRE last week (0831-0904)?
Weekly Report · 09/07 09:09
Gyre Therapeutics Highlights Capital-Efficient Global Development Strategy
TipRanks · 09/01 13:35
Weekly Report: what happened at GYRE last week (0824-0828)?
Weekly Report · 08/31 09:09
More
About GYRE
Gyre Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY, and development programs for F573, and F528. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product and discovery and development of targeted protein degrader and degrader antibody conjugate therapies.

Webull offers Gyre Therapeutics Inc stock information, including NASDAQ: GYRE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GYRE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GYRE stock methods without spending real money on the virtual paper trading platform.